Remicade Biosimilar Market Report 2026

The remicade biosimilar market size has grown exponentially in recent years. It will grow from $4.89 billion in 2025 to $5.97 billion in 2026 at a compound annual growth rate (CAGR) of 22.2%. The growth in the historic period can be attributed to high cost burden of branded biologics, patent expiry of remicade, increasing prevalence of autoimmune diseases, government support for biosimilar approvals, hospital-driven bulk procurement models.

The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $13.31 billion in 2030 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to growing demand for affordable biologic therapies, expansion of biosimilar pipelines, rising healthcare expenditure in emerging economies, increasing acceptance among clinicians and patients, favorable reimbursement frameworks. Major trends in the forecast period include increasing adoption of cost-effective biosimilars, rising prescriber confidence in infliximab biosimilars, expansion of indications across autoimmune disorders, competitive pricing and tender-based procurement, growing penetration in emerging healthcare markets.

The rising incidence of autoimmune diseases is expected to drive the growth of the Remicade biosimilar market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s tissues and organs. Remicade biosimilars provide an effective therapeutic option to manage symptoms and reduce inflammation associated with these conditions. For example, in February 2024, Arthritis Australia, an Australia-based charitable non-profit advocating for people with arthritis and musculoskeletal conditions, reported that by 2025, approximately 562,378 Australians are expected to be living with rheumatoid arthritis (RA), representing 14% of the total arthritis population. This number is projected to rise by 33% to around 748,721 by 2040. The increasing prevalence of autoimmune diseases is therefore driving demand in the Remicade biosimilar market.

Rising healthcare expenditure is also supporting growth in the Remicade biosimilar market. Healthcare expenditure refers to the total spending on healthcare goods and services within a given period. Biologic drugs, including Remicade, are typically costly, and increasing healthcare investment highlights the need for cost-effective alternatives. Biosimilars provide a more affordable option compared to originator biologics. For example, in November 2023, the Canadian Institute for Health Information reported that total health spending in Canada was projected to reach $344 billion in 2023, or $8,740 per person, reflecting a 2.8% increase from 2022, which had seen only a 1.5% growth. This rebound in healthcare investment is expected to support demand for cost-effective therapies like Remicade biosimilars.

Key players in the Remicade biosimilar market are focusing on innovative solutions, such as subcutaneous formulations, to gain a competitive edge. Subcutaneous Remicade offers an alternative administration route, allowing self-administration and potentially improving patient adherence. For instance, in March 2024, Celltrion, a South Korea-based biopharmaceutical company, launched Zymfentra, a biosimilar to Remicade (infliximab), priced at $6,181.08 for two doses over four weeks. The FDA approved it as the first subcutaneous infliximab formulation for maintaining therapy in adults with moderate-to-severe ulcerative colitis and Crohn’s disease. Eligible commercially insured patients may receive copay assistance of $5 per month, while uninsured or underinsured patients can access Zymfentra at no cost.

Major companies operating in the remicade biosimilar market are Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., BioXpress Therapeutics SA, Mabion S.A.

Europe was the largest region in the remicade biosimilar market in 2025. The regions covered in the remicade biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the remicade biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the remicade biosimilar market by increasing costs associated with imported active pharmaceutical ingredients, biologic manufacturing equipment, and cold-chain logistics, creating pricing pressure across global supply chains. These impacts are most evident in injectable dosage forms, particularly vials and prefilled syringes, and in regions dependent on cross-border biologics manufacturing such as Asia-Pacific and parts of Europe. At the same time, tariffs have encouraged localization of biologics production, strategic sourcing diversification, and domestic manufacturing investments, supporting long-term supply resilience and competitive pricing in regional markets.

The remicade biosimilar market research report is one of a series of new reports that provides remicade biosimilar market statistics, including remicade biosimilar industry global market size, regional shares, competitors with a remicade biosimilar market share, detailed remicade biosimilar market segments, market trends and opportunities, and any further data you may need to thrive in the remicade biosimilar industry. This remicade biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Remicade biosimilars are biological drugs similar to Remicade, used to treat certain autoimmune diseases in both adults and children. They are indicated for autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

The main types of Remicade biosimilars include 100 mg/10 ml and 500 mg/50 ml. The 100 mg/10 ml formulation represents a dosage unit containing 100 mg of the drug in 10 ml. These biosimilars are used to treat conditions such as ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, and plaque psoriasis. They are applied in various therapeutic areas, including blood disorders and oncology.

The remicade biosimilar market consists of sales of inflectra, renflexis, avolsa, remsima, infimab, and avolsa. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.